A Phase I Clinical Trial to Evaluate: Part A. The Safety of MTP-PE/MF59 Adjuvant Emulsion. Part B. The Safety and Immunogenicity of Env 2-3, a Yeast Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59

Name: A Phase I Clinical Trial to Evaluate: Part A. The Safety of MTP-PE/MF59 Adjuvant Emulsion. Part B. The Safety and Immunogenicity of Env 2-3, a Yeast Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59
License: Public Domain

National Institute of Allergy and Infectious Diseases (NIAID)

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

hiv-infections synthetic vaccines

hiv infections, hiv seronegativity, vaccines, synthetic, drug evaluation, adjuvants, immunologic, aids vaccines, hiv preventive vaccine, interventional, phase1

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Phase I Clinical Trial to Evaluate: Part A. The Safety of MTP-PE/MF59 Adjuvant Emulsion. Part B. The Safety and Immunogenicity of Env 2-3, a Yeast Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59

Related documents